Introduction
The majority of mammalian cells respond to cellular swelling with increases in swelling activated Cl -currents, I Cl , swell , which play critical roles in regulation of cell volume, but are also thought to be involved in apoptosis, regulation of membrane potential and release of physiologically active molecules (Lang et al., 1998; Mongin and Orlov, 2001; Hoffmann et al., 2009 ). I Cl , swell are mediated by the ubiquitously expressed volume-regulated anion channels (VRAC), which are also termed volume-sensitive outwardly rectifying (VSOR) Cl -channels, or volume-sensitive organic osmolyte/anion channels (VSOAC) (Strange et al., 1996; Nilius et al., 1997; Okada, 1997) . Throughout this manuscript we use the acronym VRAC. In spite of extensive research efforts, the molecular nature of VRAC remains unknown, and therefore functional significance of these channels is evaluated by studying the effects of pharmacological inhibitors, and correlating physiological phenomena with macroscopic whole-cell Cl -currents (Okada, 2006; Hoffmann et al., 2009) . Essentially all commonly utilized pharmacological inhibitors poorly discriminate between different Cl -channels. However, several years ago the ethacrinic acid derivative DCPIB was found to selectively block swelling-activated Cl -currents (Decher et al., 2001 ). This compound is now increasingly used for probing the involvement of VRAC in physiological and pathological processes (see for example Best et al., 2004; Abdullaev et al., 2006; Harrigan et al., 2008; Rosenberg et al., 2010; Sato et al., 2011; Min et al., 2011) .
Recently, DCPIB was found to potently protect brain tissue against experimental ischemic damage in a rat model of middle cerebral artery occlusion (Zhang et al., 2008) . The neuroprotective effects of DCPIB and the other less selective VRAC blocker, tamoxifen, were ascribed to inhibition of pathological glutamate release via VRAC (Feustel et al., 2004; Zhang et al., 2008) . Build up of glutamate in the extracellular space causes excessive activation of neuronal Ca 2+ -permeable glutamate receptor-channels of the NMDA family (N-methyl-Daspartate is the selective agonist of these receptors), leading to cytosolic Ca 2+ overload and 5 MOL #80457
neuronal death (Choi, 1992) . Based on potent reductions of ischemic brain damage by DCPIB and tamoxifen, VRAC have been suggested to represent a new and promising therapeutic target in stroke (Mongin and Kimelberg, 2005; Kimelberg, 2005; Mongin, 2007) .
It should be noted, however, that pathological glutamate release in stroke and ischemia is mediated by a number of mechanisms. In addition to opening of VRAC, disruption of transmembrane [Na + ] and [K + ] gradients causes reversal of glial Na + /K + -dependent glutamate transporters, which unload glutamate to the extracellular space (Szatkowski et al., 1990; Rossi et al., 2000) . One of these transporters, GLT-1, represents a major source of pathological accumulation of glutamate in the ischemic core (Seki et al., 1999) . Additionally, results obtained in cellular and ex vivo models suggest that reversal of the cystine/glutamate heteroexchanger (system x C -or xCT), opening of connexin hemichannels, and/or activation of purinergic P2X 7 receptor-channels may represent alternative routes for ischemic glutamate release (Ye et al., 2003; Duan et al., 2003; Fogal et al., 2007) . The cystine/glutamate heteroexchanger releases glutamate to the extracellular space and takes cystine into the cytosol, to sustain synthesis of the major cellular antioxidant glutathione, which protects cells against oxidative stress and promotes cell survival (Bannai, 1986) . However, under pathological circumstances, release of glutamate via this transporter by astrocytes or microglial cells may contribute to neuronal toxicity (Takeuchi et al., 2006; Fogal et al., 2007) . Connexin hemichannels are formed by unpaired gap junctions created by membrane proteins of the connexin family. A number of factors, which are related to ischemia and inflammation, such as metabolic depletion and/or oxidative stress can lead to opening of hemichannels allowing for release of small cytosolic molecules, including glutamate (reviewed in Orellana et al., 2009 ). Finally, long-term activation of P2X 7 purinergic receptors also leads to opening of large permeability pores capable of releasing glutamate (Duan et al., 2003) . This latter process is now thought to be mediated by the P2X 7 -receptordependent activation of the pannexin permeability pathway, formed by pannexin proteins, which 6 MOL #80457
have moderate homology to the insect gap junction molecules innexins (Pelegrin and Surprenant, 2006; Iglesias et al., 2009 ).
Based on the facts discussed above, and in view of several recent reports of strong pharmacological "cross-sensitivity" between VRAC and connexin hemichannels (Ye et al., 2009; Benfenati et al., 2009) transport experiments within 24 hrs as described below. Purity of cells cultures was verified using immunostaining with monoclonal antibodies for the astrocyte marker glial fibrillary acidic protein (GFAP), and the microglial marker OX-42 (CD11b). These procedures confirmed that astrocytic cultures were of more than 95% purity, and microglial cultures were more than 98% pure.
Preparation of Rat Brain Synaptosomes. Presynaptic nerve endings
(synaptosomes) were prepared from the forebrains of male Sprague-Dawley rats (150-180 g) according to the method of Hajos (1975) with modifications described elsewhere (Rudkouskaya et al., 2010 Glutamate Uptake Assay. Uptake rates by glia-specific glutamate transporters were measured using L- This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
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Electrophysiology. Whole cell electrophysiological recordings of swelling-activated Cl -currents were performed in cultured astrocytes as previously described (Abdullaev et al., 2006) .
Astrocytes plated on glass coverslips were treated with 300 µM dibutyryl-cyclicAMP (dbcAMP).
The resulting change in cell morphology of initially very flat cells strongly increased the probability of achieving and maintaining the whole-cell configuration during ~30-min experiment.
Whole-cell recordings were performed at room temperature with borosilicate glass electrodes fabricated using a micropipette puller (P-87, Sutter Instruments, Novato, CA), and had a resistance of 3-3.5 MΩ when filled with pipette solution. Currents were recorded using an 
Results

DCPIB Does Not Directly Block Vesicular Glutamate Release in Synaptosomes.
Since the major source of extracellular glutamate under physiological conditions is vesicular release, we started with testing DCPIB's effect on this release mechanism in rat brain synaptosomes preloaded with L-[ 3 H]glutamate. DCPIB has a ~50 μM solubility limit in physiological solutions, and completely blocks VRAC at 20 μM (Decher et al., 2001) . Therefore, we chose 20 μM as the maximal concentration for all experiments in this study. When 20 μM DCPIB was added during depolarization with high K + , it produced no effect on the Ca 2+ -dependent (vesicular) component of neurotransmitter release (Fig 1A) . However, when synaptosomes were incubated with DCPIB 30 min prior to and during stimulation with high K + , the Ca 2+ -dependent release was reduced by ~50% (Fig. 1B) . As a positive control, we pretreated synaptosomes with N-ethylmaleimide, which inhibits synaptic neurotransmitter release via modification of the NSF fusion factor and depletion of intracellular ATP (Rudkouskaya et al., 2010) . As in our previous study, N-ethylmaleimide inhibited the Ca 2+ -dependent L-[ 3 H]glutamate release by ~85% (Fig. 1B) . Overall, these results suggest that DCPIB does not have a direct effect on vesicular release machinery, but may influence it indirectly after long exposure.
DCPIB Inhibits the Glial Glutamate Transporter GLT-1, but not GLAST.
Subsequently, we tested the effects of DCPIB on the major glutamate transporters in astroglial cells, GLAST and GLT-1 (Danbolt, 2001 ). In the absence of neuronal stimulation or certain differentiation factors, astrocytes in culture predominantly express GLAST but not GLT-1 (Swanson et al., 1997) . Consistent with previous literature findings on the major contribution of GLAST, in our experiments, astroglial glutamate uptake was potently suppressed with the broad spectrum glutamate transporter blocker TBOA, but not with the selective GLT-1 inhibitor DHK ( Fig. 2A) . Glutamate uptake was also inhibited by substitution of extracellular Na + with Li + ;
This article has not been copyedited and formatted. The final version may differ from this version. confirming the Na + -dependent nature of the measured transport ( Fig. 2A) . DCPIB did not affect GLAST-mediated glutamate uptake at the maximal tested concentration of 20 μM ( Fig. 2A) .
To measure the effect of DCPIB on the activity of GLT-1, we took advantage of the known fact that primary microglial cells express this type of glutamate transporter (Nakajima et al., 2001 ). In our hands, glutamate uptake in pure microglial cultures was inhibited by ~50%
with the GLT-1 blocker DHK, and nearly completely suppressed with the broad spectrum glutamate transporter inhibitor TBOA (Fig. 2B) . These results are quantitatively indistinguishable from the original findings of (Nakajima et al., 2001) . 20 μM DCPIB suppressed glutamate uptake to the same extent as 1 mM DHK, strongly suggesting that the GLT-1 transporter is completely blocked by this tested concentration (Fig. 2B ). The effects of DCPIB and DHK were not additive (data not shown). The estimated IC 50 for DCPIB at GLT-1 was ~10 μM (Fig. 2B) .
However, the precise determination of GLT-1 sensitivity will have to be tested in GLT-1 heteroexpression systems to exclude contributions of other glutamate transporters present in microglia.
DCPIB Weakly Inhibits Cystine/Glutamate Heteroexchanger (xCT). We next tested
if DCPIB affects the cystine/glutamate heteroexchanger. This type of transport is thought to contribute to tonic glutamate release in vivo, and under pathological circumstances, may play a role in excitotoxic injury of neuronal cells (Melendez et al., 2005; Fogal et al., 2007) . To determine activity of xCT, we measured astrocytic uptake of L-[ 14 C]cystine under Na + -free conditions and in the presence of the γ-glutamyl transpeptidase inhibitor acivicin. The resulting uptake was nearly completely suppressed by the xCT blocker 1 mM L-SOS, and was reduced by ~50% in the presence of 1 mM DL-homocysteine (Fig. 3A) . These results were quantitatively similar to the previous literature reports for the xCT-expressing cell lines, confirming that the activity we measured was mediated by the cystine/glutamate heteroexchanger (Patel et al., 2004 ). In our experiments, DCPIB inhibited xCT activity only at the highest tested concentration (~50% at 20 µM, Fig. 3B ). When the effect of DCPIB on xCT-mediated L-[ 14 C]cystine uptake This article has not been copyedited and formatted. The final version may differ from this version. was tested over a shorter period of time (5 min), it was completely ineffective, while the positive control L-SOS was still able to inhibit the cystine transport of (Supplemental Fig. 1 ). These latter results suggest that DCPIB likely influences the xCT activity indirectly, perhaps via decreasing the intracellular L-glutamate levels, as shown in our previous study (Hyzinski-Garcia et al.,
2011).
Comparison of DCPIB's Effects on VRAC and Connexins Hemichannels. Recent studies found that many commonly used VRAC inhibitors, such as NPPB, IAP-94, and tamoxifen, potently block connexin hemichannels (Ye et al., 2009 4A ). In contrast to its effects on connexins, 18-αGA did not affect hypoosmotic activation of glutamate release via VRAC (Fig. 4B) . DCPIB dose-dependently blocked the connexinmediated release under the CMF conditions with an IC 50 of ~1 µM (Fig. 4A, C) . Predictably, DCPIB potently inhibited glutamate release via VRAC with an apparent IC 50 of ~1 µM, which was consistent with our previous findings and close to the published IC 50 of 4 µM for VRAC activity measured using electrophysiology approach (Decher et al., 2001; Abdullaev et al., 2006 ).
To further demonstrate that DCPIB has a direct effect on connexin hemichannels, we performed several additional controls. First, we increased tonicity of CMF medium to reduce astrocytic cell volume and block VRAC by adding 150 mM mannitol. Addition of mannitol had no significant effect on CMF-induced glutamate release (~15% inhibition, data not shown), but completely blocked VRAC (data not shown). Second, we additionally validated the ability of 18-α GA to discriminate between connexins and VRAC using an electrophysiological approach.
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Whole cell Cl − currents were dramatically increased in cells subjected to hypoosmotic medium (Fig. 4D) . Contribution of VRAC to these currents was verified by biophysical analysis.
Moderate outward rectification and time-dependent inactivation at positive potential (Fig. 4E ) are the signature characteristics of VRAC (Okada, 1997) . 18-αGA at the concentration of 10 µM did not affect VRAC currents (Fig. 4D, F) . As in our previous study (Abdullaev et al., 2006) , DCPIB potently suppresses swelling activated Cl − currents, when added alone or in combination with 18-αGA (Fig. 4D, F) .
Finally, we downregulated expression of the major astrocytic connexin, Cx43, using gene-specific siRNA constructs. Three different siRNAs reduced Cx43 mRNA levels by 80-90%
as verified by quantitative RT-PCR (Fig. 5A) , and Cx43 protein levels by >90% as verified by
Western blot analysis (Fig. 5B) . In Western blotting, two major immunopositive bands were detected at ~43-47 kD, which was close to the predicted molecular weight of Cx43 protein (Fig.   5B ). The presence of multiple Cx43 bands can be explained by protein phosphorylation (see for example (Musil and Goodenough, 1991) . The most effective Cx43 siRNA (siCx43-1) was used in glutamate release assays. It inhibited the CMF-stimulated glutamate efflux by >90%, in a manner that was indistinguishable from DCPIB ( Fig. 5C ).
Altogether, the results presented in this section strongly affirm that Cx43 hemichannels represent a molecular target for DCPIB. Furthermore, both glutamate release measurements and electrophysiological assays establish 18-αGA as a pharmacological tool allowing discrimination between connexins and VRAC.
DCPIB Potentiates Glutamate Release Associated with Activation of P2X 7
Receptors. Literature data suggest that activation of the P2X 7 purinergic receptor-channels can trigger glutamate release from astrocytes (Duan et al., 2003) . Recent studies indicate that the P2X 7 receptor does not form a glutamate-permeable pore itself, but rather activates a separate permeability pathway formed by pannexins (Pelegrin and Surprenant, 2006; Iglesias et al., 2009) . To test the impact of DCPIB on the P2X 7 /pannexin complexes, we used the P2X 7
This article has not been copyedited and formatted. The final version may differ from this version. inhibitor AZ 10606120 (Fig. 6A) . To test for downstream involvement of pannexins, we used 2 mM probenecid that discriminates between the pannexin and connexin permeability pathways (Silverman et al., 2008) . Probenicid completely prevented the BzATP-stimulated D-[ 3 H]aspartate efflux, confirming that it is mediated by pannexins (Fig. 6A) (Park et al., 2009; Lee et al., 2010) . The Best1-mediated anion currents are transiently activated by agonists for numerous phospholipase C-linked G-protein-coupled receptors, including metabotropic purinergic receptors (Park et al., 2009 (Abdullaev et al., 2006; Heacock et al., 2006; Liu et al., 2009) . These data do not necessarily point to activation of Best1 channels since ATP was previously shown to activate the DCPIB-sensitive VRAC This article has not been copyedited and formatted. The final version may differ from this version. channels (Mongin and Kimelberg, 2002; Liu et al., 2009; Akita et al., 2011) . VRAC can be regulated by various G-protein coupled receptors even in the absence of cell swelling (reviewed in (Fisher et al., 2010 (Fig. 7B) , therefore suggesting that such release is at least partially mediated by an anion channel other than VRAC. In addition to Best1, niflumic acid also potently blocks Ca 2+ -activated Cl − channels of the Anoctamin/TMEM16 family (Verkman and Galietta, 2009 Fig. 2) . Unfortunately, these results were inconclusive because, while Western blot analysis found heteroexpressed hBest1 protein HEK293 cells, we were unable to detect Best1 upregulation in astrocytes (Supplemental Fig. 2) . Overall, the results presented in this section suggest that DCPIB blocks ATP-stimulated and niflumic acid-sensitive glutamate release pathway the molecular nature of which remains uncertain (see text below for additional discussion).
Discussion
The major finding of this work is that DCPIB, which is marketed as the selective inhibitor of VRAC, strongly affects two other glutamate transport pathways, namely connexin hemichannels formed by Cx43 and the glia specific glutamate transporter GLT-1. In addition, extended exposures to high concentrations of DCPIB (20 μM for ≥30 mins) weakly suppress the activity of the cystine/glutamate exchanger (xCT) and vesicular glutamate release, both effects likely occurring via an indirect mechanism. Other physiologically and pathologically relevant glutamate transporters were either not directly affected by DCPIB (GLAST) or moderately potentiated (P2X 7 /pannexin complexes). The graphic summary of our findings is presented in Fig. 8 . The newly identified pharmacological properties of DCPIB are important for understanding ischemia pathology and deciphering mechanisms responsible for neuroprotective actions of this compound in animal stroke models.
DCPIB was originally identified as a highly selective VRAC blocker based upon its effects on an array of chloride channels, tested using an electrophysiological approach (Decher et al., 2001) . Since the molecular identity of VRAC has yet to be identified, DCPIB represents a highly useful pharmacological tool in studies examining physiological and pathological roles of VRAC (see Introduction for references). Two VRAC blockers, tamoxifen and DCPIB, have been found to potently reduce ischemic brain damage, and additionally inhibited the intra-ischemic release of the excitatory neurotransmitter glutamate in several rodent models of stroke (Kimelberg et al., 2000; Kimelberg et al., 2003; Feustel et al., 2004; Zhang et al., 2008) .
Because, tamoxifen and DCPIB potently block swelling-activated glutamate release via VRAC in vitro (Abdullaev et al., 2006) , the simplest interpretation of the aforementioned in vivo data is that VRAC is largely responsible for both pathological glutamate release and tissue damage in stroke. The strength of this conclusion was built on the assumed selectivity of DCPIB. The data obtained in the present study call for re-evaluation of the importance of VRAC in cerebral ischemia. In particular, the effects of DCPIB may be determined by inhibition of connexin hemichannels. As seen in Fig. 4 and 5, DCPIB has a similar IC 50 for both VRAC and connexin hemichannels composed by the major astrocytic connexin, Cx43. This may not be surprising as substantial pharmacological "cross-reactivity" between VRAC and Cx hemichannel blockers, including Cx inhibition by tamoxifen, has been reported in several studies (Ye et al., 2009; Benfenati et al., 2009 ). As previously found by Ye et al. (2009) , 18-αGA discriminates between VRAC and Cx permeability pathways and inhibits only connexins. We validated this finding using two approaches: electrophysiology and glutamate release assays. In our hands, 10 μM 18-αGA completely blocked Cx hemichannels, but had no effect on VRAC.
Another glutamate transporter strongly suppressed by DCPIB, is the glial GLT-1, which plays a major role in maintenance of low extracellular glutamate levels (Rothstein et al., 1996) .
Our experiments in microglial cells indicate that DCPIB potently blocks GLT-1 at 20 μM.
Interestingly, it had no effect on another glial glutamate transporter GLAST. Thus, DCPIB appears to discriminate between GLT-1 and GLAST when applied at concentrations much lower than submillimolar concentrations for the commonly used GLT-1 inhibitor, DHK. In the context of brain physiology, perfusion of DCPIB in vivo may impair glutamate uptake by acting at the GLT-1 transporter. At least under normal physiological conditions, DCPIB does not appears to affect extracellular glutamate homeostasis, because perfusion of this compound via a microdialysis probe does not increase microdialysate glutamate levels (Zhang et al., 2008) . In severe ischemia, GLT-1 has been reported to work in "reverse" mode and release glutamate to the extracellular space due to disrupted membrane ionic gradients (Seki et al., 1999) . We believe that the neuroprotective properties of DCPIB in ischemia are unlikely related to inhibition of GLT-1. In the ischemic penumbra, the clinically relevant area of less severe ischemia, DCPIB and tamoxifen suppress pathological glutamate release, while the GLT-1 blocker DHK produces the opposite effect (Feustel et al., 2004) .
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We found no direct effect of DCPIB on vesicular glutamate release and weak inhibition of the cystine/glutamate heteroexchanger at the maximal tested concentration (20 μM). The latter effect is likely indirect because it cannot be seen during short incubation periods.
Paradoxically, DCPIB increased glutamate release associated with the P2X 7 receptor-induced activation of pannexins, but only at the highest concentration tested. Several studies proposed a role for the pannexin permeability pathway in ischemic damage and death of neuronal cells, in vitro and in vivo (Thompson et al., 2006; Bargiotas et al., 2011) . Therefore, DCPIB can theoretically exacerbate ischemic brain damage by promoting pannexin channel opening. Yet, keeping in mind the potent neuroprotective actions of DCPIB in rodent stoke, its actions on pannexins appear to be insignificant. Either DCPIB does not reach high enough levels in the ischemic brain, or the contribution of pannexins to stroke pathology is minor.
Another potential target for DCPIB is the Ca 2+ -activated Cl − channels, which may be activated in ischemia by sustained elevations in intracellular [Ca 2+ ]. The original study on DCPIB selectivity, found no effect of this compound on the Ca 2+ -activated Cl − currents, but this was tested only in one cell type, calf pulmonary artery endothelial cells (Decher et al., 2001) .
Two recent publications identified Best1 as the endogenous Ca 2+ -activated Cl − channel that is responsible for release of γ-aminobutyric acid (GABA) from rodent astroglial cells in vitro and in vivo (Park et al., 2009; Lee et al., 2010) . The Best1 channel is also permeable to glutamate (Park et al., 2009 ). In our experiments, stimulation of primary astrocytes with ATP triggered release of the glutamate analogue D-[ 3 H]aspartate via a pathway sensitive to niflumic acid, which was also strongly inhibited by DCPIB. The niflumic acid sensitivity clearly discriminated this release pathway from VRAC channels. VRAC can be also activated in a Ca 2+ -sensitive manner by ATP and other G-protein-coupled receptors but they are largely insensitive to niflumic acid (Pedersen et al., 1998; Mongin and Kimelberg, 2002; Akita et al., 2011; Fisher et al., 2010) . The niflumic acid sensitivity, however, is not sufficient to infer contribution of Best1
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Our present findings call for additional experiments clarifying the role of VRAC in stroke pathology. In particular, by comparing the effects of DCPIB and 18α-glycyrrhetinic acid on pathological glutamate release and tissue damage, it will be possible to elucidate the relative pathological importance of VRAC and connexin hemichannels in stroke.
